EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB
Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB ) .
09 septiembre 2020
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) Today Announced That the Company Will Webcast its Corporate Presentations at The Following Virtual Investor Conferences .